ACell, Inc. is a regenerative medicine company. The Company is focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. Its products utilize its porcine urinary bladder matrix platform technology. It manufactures extracellular matrix (ECM), products that utilize porcine urinary bladder matrix (UBM). It markets MicroMatrix, a particulate formulation, and Cytal Wound Matrix products, in sheet formulations, for the management of acute, surgical, chronic and tunneling wounds and partial thickness burns. It also markets Gentrix Surgical Matrix products, in sheet formulations, for the reinforcement of soft tissue in certain surgical applications, such as for hernia repair.